Transitional B cell subsets – a convincing predictive biomarker for allograft loss? by Burton, Hannah Marguerite Mckenna & Dorling, Anthony
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Burton, H. M. M., & Dorling, A. (2017). Transitional B cell subsets – a convincing predictive biomarker for
allograft loss? Kidney International, 91(1), 18-20. [KI-09-16-1329].
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
	Transitional	B	cell	subsets	–	a	convincing	predictive	biomarker	for	allograft	loss?	
	
	
Hannah	Burton	MA,	Anthony	Dorling	PhD	
	
MRC	Centre	for	Transplantation,		
King’s	College	London,		
Guy’s	Hospital,		
London		
SE1		9RT	
	
*Correspondence	should	be	addressed	to	Anthony	Dorling.	Email:	anthony.dorling@kcl.ac.uk;	
Tel:+44	2071885880.	Fax:	+442071885660	
	
	
	 	
Abstract:		
In	this	issue,	Cherukuri	and	colleagues	describe	a	convincing	association	between	the	proportion	
of	transitional	B	lymphocyte	subsets	in	kidney	transplant	recipients	and	long-term	outcomes,	and	
present	a	biologically	plausible	mechanism,	based	on	differential	ability	of	T1	and	T2	cells	to	
regulate	in	vitro	T	cell	responses	to	explain	the	link.		Further	work	is	clearly	needed	to	validate	
their	claim	that	measurement	of	T1/T2	ratios	may	represent	a	reliable	and	reproducible	predictive	
biomarker	of	transplant	outcomes.	
	 	
The	majority	of	kidney	transplants	fail	before	the	end	of	the	natural	lifespan	of	the	recipient;	most	
because	of	immune	mediated	injury	[1]	and	one	of	the	major	challenges	facing	clinicians	involved	in	
renal	transplantation	is	how	to	improve	long-term	allograft	survival.		However,	an	incomplete	
understanding	of	the	complex	mechanisms	driving	immune-mediated	damage	and	the	difficulties	of	
identifying	patients	at	higher	risk	of	graft	loss	hamper	progress	in	this	area.	Coupled	with	the	
potential	benefits	of	identifying	those	at	low	risk	of	graft	failure,	in	whom	the	detrimental	effects	of	
excess	immunosuppression	might	be	avoided,	progress	in	identifying	new	predictive	biomarkers	for	
allograft	outcome	is	desirable.	
Over	recent	years	there	has	been	an	explosion	of	interest	in	the	role	and	importance	of	B	
lymphocytes	in	transplantation,	beyond	their	role	in	antibody	production.	It	is	now	well	recognised	
that	they	play	a	complex	role	in	renal	transplant	recipients,	capable	of	both	promoting	and	
regulating	anti-donor	T	cell	responses	[2].	The	precise	phenotype	of	human	regulatory	B	cells	is	still	
incompletely	defined,	but	‘transitional’	cells,	which	regulate	via	production	of	IL-10,	are	perhaps	the	
most	studied	population	[3].	Transitional	B	cells	(immature	B	cells	that	have	recently	migrated	from	
the	bone	marrow	into	the	peripheral	blood)	are	characterised	by	expression	of	high	levels	of	IgM,	
IgD,	CD24,	CD38	and	CD10.		In	this	issue,	Cherukuri	and	colleagues	build	on	previous	work	and	report	
that	the	relative	proportions	of	T1	and	T2	subsets,	differentiated	on	the	basis	of	the	level	of	CD24	
and	CD38	expression,	predict	regulatory	B	cell	activity	and	is	significantly	predictive	of	subsequent	
graft	dysfunction	[4]	.	
This	group	has	already	contributed	significantly	to	our	understanding	of	transitional	B	cell	biology	
after	kidney	transplantation.	In	previous	work,	they	showed	that	multiple	B	cell	subpopulations	
secreted	IL-10	and	were	capable	of	suppression	in	vitro	[5],	but	that	non-transitional	populations	
also	typically	secreted	TNFα,	which	inhibited	regulatory	activity.	The	regulatory	phenotype	of	
healthy	transitional	B	cells	after	polyclonal	stimulation	was	therefore	due	to	the	uniquely	polarised	
production	of	IL-10.		However,	transitional	B	cells	from	patients	suffering	graft	rejection	had	a	
diminished	ability	to	regulate	in	vitro	T	cell	responses	due	to	co-secretion	of	TNFα	with	IL-10	(rather	
than	a	reduced	ability	to	secrete	IL-10).	This	‘defect’	associated	with	poorer	graft	outcomes	over	3	
years.	
In	this	new	work,	they	study	the	relative	proportions	of	transitional	cell	subsets	in	two	independent	
populations	of	kidney	transplant	recipients;	the	first	a	group	undergoing	late	‘for-cause’	biopsy,	and	
the	second,	patients	with	stable	function	two	years	post-enrolment	to	an	induction	trial	comparing	
alemtuzumab	with	basiliximab.		
In	the	first	group	of	45	patients,	those	with	subsequent	functional	deterioration	(defined	as	halving	
of	eGFR	or	graft	loss)	were	found	to	have	a	significantly	lower	frequency	and	absolute	number	of	
transitional	B	cells	than	those	with	stable	function;	more	specifically	there	was	a	very	significant	
decrease	in	the	numbers	of	T1	cells,	such	that	the	T1/T2	ratio	exhibited	by	those	patients	with	
deteriorating	function	was	significantly	lower	than	those	with	stable	function.	ROC	curve	analysis	
demonstrated	that	the	T1/T2	ratio	in	peripheral	blood	collected	at	the	time	of	for-cause	biopsy	
strongly	predicted	the	development	of	late	allograft	dysfunction	and	death-censored	graft	loss.	Of	
particular	interest	is	the	detailed	analysis	of	the	25	patients	with	biopsy-proven	rejection,	in	whom	
the	T1/T2	ratio	strongly	classified	graft	dysfunction	compared	to	stable	function,	whilst	the	
histological	parameters	based	on	BANFF	scores	lacked	predictive	capacity.	
These	findings	were	replicated	in	the	second	group	of	97,	in	which	patients	were	allocated	to	either	
a	“stable”	or	“deteriorating”	group	according	to	their	clinical	progress	over	the	subsequent	five	
years.	Again,	patients	with	deteriorating	function	were	found	to	have	a	significantly	lower	frequency	
and	absolute	number	of	T1	cells,	with	a	lower	T1/T2	ratio	than	patients	with	stable	function.	ROC	
curve	analysis	again	confirmed	the	T1/T2	ratio	to	be	a	strong	predictor	of	allograft	function.	
Subsequent	multivariate	Cox	analysis	showed	the	T1/T2	ratio	was	independently	associated	with	
declining	allograft	function	in	both	cohorts	of	patients,	whereas	other	parameters	examined,	
including	the	presence	of	DSA	and	eGFR,	were	not	able	to	predict	late	allograft	decline.	
To	link	these	new	data	to	their	earlier	work	they	show	that	the	most	immature	T1	subset	of	
transitional	cells,	characterised	by	the	highest	expression	of	CD24	and	CD38,	had	the	greatest	
polarisation	of	cytokine	production	towards	IL-10	after	polyclonal	stimulation,	such	that	the	IL-
10/TNFα	ratio	was	significantly	higher	in	T1	compared	to	T2	cells.	The	impact	of	a	low	ratio	of	T1/T2	
was	therefore	to	reduce	the	regulatory	ability	of	the	whole	transitional	B	cell	population	and	this	
explains	the	‘defect’	in	B	cell	regulatory	ability	they	previously	associated	with	poor	graft	outcomes.	
Measuring	the	T1/T2	ratio	of	peripheral	blood	B	cells	by	flow	cytometry	is	clearly	a	more	easily	
measurable	predictive	biomarker	than	measuring	the	cytokine	secretion	profiles	of	polyclonally	
activated	B	cells.		
	
There	are	several	potentially	problematic	issues	with	this	work,	which	the	authors	discuss.		First	is	
the	issue	about	distinguishing	between	T1	and	T2	cells;	the	threshold	of	CD24	and	CD38	expression	
used	to	define	the	two	subgroups	is	somewhat	arbitrary.		However,	the	authors	have	attempted	to	
establish	a	sound	footing	for	their	methodology,	basing	their	flow	cytometric	gating	strategy	on	
earlier	reports	of	B	cell	repopulation	in	patients	treated	with	rituximab,	in	whom	a	discrete	
population	of	T1	cells	repopulates	peripheral	blood	from	the	bone	marrow,	followed	by	the	
appearance	of	T2	cells	with	distinctly	lower	expression	of	both	markers.	In	healthy	volunteers,	these	
gates	gave	a	T1/T2	ratio	of	approximately	1:3	and	the	same	gates	were	applied	to	patient	samples	in	
a	non-biased	manner.	
The	second	issue	is	that	meaningful	interpretation	of	the	results	also	relies	on	the	allocation	of	
patients	to	either	the	“stable”	or	“deteriorating”	groups,	which	rests	on	how	deteriorating	function	
is	defined.	Here	the	authors	choose	halving	of	eGFR	as	an	established	surrogate	for	the	progression	
of	kidney	disease,	or	alternatively	the	harder	endpoint	of	graft	loss.	They	sought	to	address	the	
recognised	association	between	deteriorating	renal	function	and	overall	numbers	of	B	cells	in	the	
peripheral	blood	by	examining	the	relationship	between	transitional	cell	subsets	and	eGFR;	although	
a	weak	positive	correlation	was	observed	in	the	larger	patient	group,	none	was	seen	in	patients	
undergoing	for-cause	biopsy.	Furthermore	the	multivariate	Cox	proportionate	hazard	analysis,	which	
included	eGFR	as	a	covariate,	demonstrated	the	T1/T2	ratio	was	independently	associated	with	graft	
deterioration.	
Finally,	immunological	biomarker	discovery	in	renal	transplant	recipients	is	made	more	difficult	by	
the	potential	confounding	impact	of	immunosuppression	on	different	cell	populations	[6].	These	
authors	have	previously	reported	higher	numbers	of	B	cells,	including	transitional	subsets,	in	
patients	receiving	induction	alemtuzumab	compared	to	basiliximab	[7]	and	in	this	new	data,	twice	as	
many	patients	with	the	highest	T1/T2	ratios	had	received	alemtuzumab.	The	authors	were	careful	to	
show	that,	irrespective	of	their	induction	regimen,	patients	with	a	low	T1/T2	ratio	had	a	comparable	
degree	of	graft	deterioration	and	change	in	eGFR.	An	additional	consideration	was	that	significantly	
more	patients	found	to	have	a	low	T1/T2	ratio	were	taking	maintenance	prednisolone,	but	once	
again	the	authors	do	a	careful	subgroup	analysis	and	show	that	the	association	of	outcome	with	low	
T1/T2	ratio	was	independent	of	steroid	use.		
In	summary,	Cherukuri	and	colleagues	propose	that	the	relative	proportions	of	transitional	B	cell	T1	
and	T2	subsets	in	peripheral	blood	can	serve	as	a	biomarker	for	late	graft	deterioration	in	renal	
transplant	recipients,	with	a	plausible	biological	explanation	for	the	association	with	graft	outcomes,	
based	on	the	functional	differences	between	T1	and	T2	cells	at	regulating	T	cell	responses	(Fig	1).		
Their	findings	are	complementary	to	and	build	on	their	previous	work,	and	are	consistent	with	other	
recent	work	examining	transitional	B	cells	in	the	early	post-transplant	period	[8,	9].	Of	particular	
interest	for	future	work	will	be	understanding	the	dynamic	changes	in	transitional	cell	subsets	in	
individual	patients	and	relating	this	to	changes	in	eGFR,	as	well	as	understanding	whether	specific	
treatments	influence	the	relationship	between	T1	and	T2	subsets.	Further	study	of	transitional	B	
cells	to	determine	the	generalizability	of	these	observations,	and	to	understand	the	importance	of	
regulation	of	the	anti-donor	alloresponse	by	B	cells	is	clearly	required.	
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